Cargando…

Overall Survival Benefits of First-Line Treatments for Asian Patients with Advanced Epidermal Growth Factor Receptor-Mutated NSCLC Harboring Exon 19 Deletion: A Systematic Review and Network Meta-Analysis

SIMPLE SUMMARY: Survival benefits and clinical responsiveness have been exhibited by various generations of EGFR-tyrosine kinase inhibitors (TKIs) in numerous randomized-controlled trials for EGFR-mutated advanced non-small-cell lung cancer (NSCLC) over the past two decades. However, the efficacy, e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chan, Sik-Kwan, Choi, Horace Cheuk-Wai, Lee, Victor Ho-Fun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Systematic Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9316403/ https://www.ncbi.nlm.nih.gov/pubmed/35884423 http://dx.doi.org/10.3390/cancers14143362

Ejemplares similares

Overall Survival Benefits of First-Line Treatments for Asian Patients With Advanced EGFR-Mutated NSCLC Harboring L858R Mutation: A Systematic Review and Network Meta-Analysis
por: Chan, Sik-Kwan, et al.
Publicado: (2022)

Cost-Effectiveness of Intranasal Live-Attenuated Influenza Vaccine for Children: A Systematic Review
por: Chan, Kenneth Sik-Kwan, et al.
Publicado: (2022)

Treatment-Related Adverse Events of Combination EGFR Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor in EGFR-Mutant Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Chan, Daisy Wai-Ka, et al.
Publicado: (2022)

Gastrointestinal malignancies harbor actionable MET exon 14 deletions
por: Lee, Jeeyun, et al.
Publicado: (2015)

Continuation of Tyrosine Kinase Inhibitor is Associated with Survival Benefit in NSCLC Patients with Exon 19 Deletion after Solitary Progression
por: Na, Feifei, et al.
Publicado: (2017)

Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations
por: Lin, Ling, et al.
Publicado: (2020)

Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation?
por: Joshi, Amit, et al.
Publicado: (2017)

Generation and Characterization of a Mouse Model Harboring the Exon-3 Deletion in the Cardiac Ryanodine Receptor
por: Liu, Yingjie, et al.
Publicado: (2014)

First-Line Atezolizumab Plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
por: Chiang, Chi-Leung, et al.
Publicado: (2021)

Case Report: Afatinib Treatment in a Patient With NSCLC Harboring a Rare EGFR Exon 20 Mutation
por: Zöchbauer-Müller, Sabine, et al.
Publicado: (2021)

First-line tepotinib for a very elderly patient with metastatic NSCLC harboring MET exon 14 skipping mutation and high PD-L1 expression
por: Inno, Alessandro, et al.
Publicado: (2023)

Cost-effectiveness of Pembrolizumab as a Second-Line Therapy for Hepatocellular Carcinoma
por: Chiang, Chi-leung, et al.
Publicado: (2021)

PMON115 Long term follow-up of patient with gigantism harboring an exon 2 deletion in the AIP gene
por: Huayllas, Martha Katherine Paniagua, et al.
Publicado: (2022)

The overall survival benefit in Chinese ALK(+) NSCLC patients received targeted therapies
por: Tian, Guangming, et al.
Publicado: (2022)

Detection of internal exon deletion with exon Del
por: Guo, Yan, et al.
Publicado: (2014)

Health-Related Quality of Life in Asian Differentiated Thyroid Cancer Survivors
por: Chan, Wing-Lok, et al.
Publicado: (2021)

Inconsistent clinical outcomes following afatinib treatment in NSCLC patients harboring uncommon epidermal growth factor receptor mutation
por: Dong, Wei, et al.
Publicado: (2022)

Successful Treatment of Lung Adenocarcinoma with Epidermal Growth Factor Receptor Compound Mutations Involving Exon 19 Deletion and Exon 20 Insertion by Afatinib
por: Ikeuchi, Tomoyuki, et al.
Publicado: (2019)

Non-small cell lung cancer harboring EGFR G724S mutation and exon 19 deletion responded to afatinib monotherapy after multiple lines of target therapies
por: Cortiula, Francesco, et al.
Publicado: (2022)

Rapid Disease Progression in a Patient with Advanced NSCLC Harboring a Germline MET Exon 14 Skipping Mutation: A Case Report
por: Jiao, Yang, et al.
Publicado: (2021)

Amivantamab-Vmjw: A Novel Treatment for Patients with NSCLC Harboring EGFR Exon 20 Insertion Mutation after Progression on Platinum-Based Chemotherapy
por: Shah, Vishal, et al.
Publicado: (2023)

Benefit of Asian pigmented rice bioactive compound and its implication in breast cancer: a systematic review
por: Nafisah, Wirdatun, et al.
Publicado: (2023)

Whole-genome and Epigenomic Landscapes of Malignant Gastrointestinal Stromal Tumors Harboring KIT Exon 11 557–558 Deletion Mutations
por: Ohshima, Keiichi, et al.
Publicado: (2023)

Complex Mutations & Subpopulations of Deletions at Exon 19 of EGFR in NSCLC Revealed by Next Generation Sequencing: Potential Clinical Implications
por: Marchetti, Antonio, et al.
Publicado: (2012)

Analysis of progression-free survival of first-line tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring leu858Arg or exon 19 deletions
por: Kuan, Feng-Che, et al.
Publicado: (2016)

Apatinib as a third- or further- line treatment in patients with advanced NSCLC harboring wild-type EGFR
por: Fang, Shencun, et al.
Publicado: (2017)

Complex Haplotypes of GSTM1 Gene Deletions Harbor Signatures of a Selective Sweep in East Asian Populations
por: Saitou, M., et al.
Publicado: (2018)

Response to Brigatinib Targeted Therapy in Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 19 Deletion, T790M, and cis-C797S Triple Mutations: A Case Report
por: Chen, Zi-Wei, et al.
Publicado: (2022)

Aumolertinib in NSCLC with leptomeningeal involvement, harbouring concurrent EGFR exon 19 deletion and TP53 comutation: a case report
por: Qin, Zhiquan, et al.
Publicado: (2023)

Prognostic Biomarkers for Survival in Nasopharyngeal Carcinoma: A Systematic Review of the Literature
por: Islam, Kazi Anisha, et al.
Publicado: (2022)

An entire exon 3 germ-line rearrangement in the BRCA2 gene: pathogenic relevance of exon 3 deletion in breast cancer predisposition
por: Muller, Danièle, et al.
Publicado: (2011)

Management of Oligoprogression in Patients with Metastatic NSCLC Harboring ALK Rearrangements
por: Pisano, Chiara, et al.
Publicado: (2022)

Prognostic analysis of patients with non-small cell lung cancer harboring exon 19 or 21 mutation in the epidermal growth factor gene and brain metastases
por: Wang, Jing, et al.
Publicado: (2020)

Clinical outcomes of advanced NSCLC patients with different EGFR exon 19 deletion subtypes treated with first‐line tyrosine kinase inhibitors: A single‐center ambispective cohort study
por: Gu, Yangchun, et al.
Publicado: (2023)

Lower starting dose of afatinib for the treatment of metastatic lung adenocarcinoma harboring exon 21 and exon 19 mutations
por: Chen, Yi-Chieh, et al.
Publicado: (2021)

Technical Evaluation of the COBAS EGFR Semiquantitative Index (SQI) for Plasma cfDNA Testing in NSCLC Patients with EGFR Exon 19 Deletions
por: González de Aledo-Castillo, José Manuel, et al.
Publicado: (2021)

Efficacy of gefitinib in epidermal growth factor receptor-activating mutation-positive nonsmall cell lung cancer: Does exon 19 deletion differ from exon 21 mutation?
por: Joshi, Amit, et al.
Publicado: (2018)

Budget Impact Analysis of Afatinib for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 19 Deletions or Exon 21 Substitution Mutations in a U.S. Health Plan
por: Graham, Jonathan, et al.
Publicado: (2018)

Prognosis and Concurrent Genomic Alterations in Patients With Advanced NSCLC Harboring MET Amplification or MET Exon 14 Skipping Mutation Treated With MET Inhibitor: A Retrospective Study
por: Liu, Li, et al.
Publicado: (2021)

A first case report of clinical response to targeted therapy in a patient with primary myoepithelial carcinoma of the lung harboring EGFR exon 19 deletion
por: Xie, Xiaohong, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_d5ikrgmnlhqrcii9o0upp4nfka